<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Genes associated with lymphoproliferative disease</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Genes associated with lymphoproliferative disease</h1>
<div class="graphic"><div class="figure"><div class="ttl">Genes associated with lymphoproliferative disease</div><div class="cntnt"><table cellspacing="0"><colgroup width="15%"></colgroup><colgroup width="35%"></colgroup><colgroup width="15%"></colgroup><colgroup width="35%"></colgroup> <tbody> <tr> <td class="subtitle1">Gene abbreviation</td> <td class="subtitle1">Full gene name</td> <td class="subtitle1">Inheritance</td> <td class="subtitle1">Disorder name/phenotype<sup>*</sup></td> </tr> <tr> <td><em>ADA2</em></td> <td>Adenosine deaminase 2</td> <td>AR</td> <td>Vasculitis, autoinflammation, immunodeficiency, and hematologic defects syndrome</td> </tr> <tr class="highlight_lght_gray_text"> <td><em>CASP8</em></td> <td>Caspase 8</td> <td>AR</td> <td>Autoimmune lymphoproliferative syndrome, type IIB</td> </tr> <tr> <td><em>CASP10</em></td> <td>Caspase 10</td> <td>AD</td> <td>Autoimmune lymphoproliferative syndrome, type IIA</td> </tr> <tr class="highlight_lght_gray_text"> <td><em>CD27</em></td> <td>CD27 molecule</td> <td>AR</td> <td>Lymphoproliferative syndrome 2</td> </tr> <tr> <td><em>CD70</em></td> <td>CD70 molecule</td> <td>AR</td> <td>Lymphoproliferative syndrome 3</td> </tr> <tr class="highlight_lght_gray_text"> <td><em>CDC42</em></td> <td>Cell division cycle 42</td> <td>AD</td> <td>CDC42 deficiency</td> </tr> <tr> <td><em>CTLA4</em></td> <td>Cytotoxic T-lymphocyte-associated protein 4</td> <td>AD</td> <td>Autoimmune lymphoproliferative syndrome, type V</td> </tr> <tr class="highlight_lght_gray_text"> <td><em>FAS</em></td> <td>Fas cell surface death receptor</td> <td>AD</td> <td>Autoimmune lymphoproliferative syndrome, type IA</td> </tr> <tr> <td><em>FASLG</em></td> <td>Fas ligand</td> <td>AD</td> <td>Autoimmune lymphoproliferative syndrome, type IB</td> </tr> <tr class="highlight_lght_gray_text"> <td><em>FCHO1</em></td> <td>FCH domain only protein 1</td> <td>AR</td> <td>Immunodeficiency 76</td> </tr> <tr> <td><em>IL2RB</em></td> <td>Interleukin 2 receptor beta</td> <td>AR</td> <td>Immunodeficiency 63 with lymphoproliferation and autoimmunity</td> </tr> <tr class="highlight_lght_gray_text"> <td><em>ITK</em></td> <td>Interleukin 2-inducible T cell kinase</td> <td>AR</td> <td>Lymphoproliferative syndrome 1</td> </tr> <tr> <td><em>KRAS</em></td> <td>Kras protooncogene GTPase</td> <td>AD</td> <td>RAS-associated autoimmune leukoproliferative disorder</td> </tr> <tr class="highlight_lght_gray_text"> <td><em>LAT</em></td> <td>Linker for activation of T cells</td> <td>AR</td> <td>Immunodeficiency 52</td> </tr> <tr> <td><em>LRBA</em></td> <td>LPS-responsive beige-like anchor protein</td> <td>AR</td> <td>Common variable immunodeficiency-8 with autoimmunity</td> </tr> <tr class="highlight_lght_gray_text"> <td><em>MAGT1</em></td> <td>Magnesium transporter 1</td> <td>XLR</td> <td>X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection, and neoplasia</td> </tr> <tr> <td><em>NCKAP1L</em></td> <td>NCK-associated protein 1-like</td> <td>AR</td> <td>Immunodeficiency 72 with autoinflammation</td> </tr> <tr class="highlight_lght_gray_text"> <td><em>NRAS</em></td> <td>Nras protooncogene GTPase</td> <td>AR</td> <td>RAS-associated autoimmune leukoproliferative disorder</td> </tr> <tr> <td><em>PIK3CD</em></td> <td>Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta</td> <td>AD</td> <td>Activated PI3K delta syndrome 1</td> </tr> <tr class="highlight_lght_gray_text"> <td><em>PIK3R1</em></td> <td>Phosphoinositide-3-kinase regulatory subunit 1</td> <td>AD</td> <td>Activated PI3K delta syndrome 2</td> </tr> <tr> <td><em>PRKCD</em></td> <td>Protein kinase C delta</td> <td>AR</td> <td>Autoimmune lymphoproliferative syndrome, type III</td> </tr> <tr class="highlight_lght_gray_text"> <td><em>RASGRP1</em></td> <td>RAS guanyl-releasing protein 1</td> <td>AR</td> <td>Immunodeficiency 64</td> </tr> <tr> <td><em>RBCK1</em></td> <td>RANBP2-type and C3HC4-type zinc finger containing 1</td> <td>AR</td> <td>Polyglucosan body myopathy 1 with or without immunodeficiency</td> </tr> <tr class="highlight_lght_gray_text"> <td><em>RIPK1</em></td> <td>Receptor-interacting serine/threonine kinase 1</td> <td>AD</td> <td>Autoinflammation with episodic fever and lymphadenopathy</td> </tr> <tr> <td><em>SH2D1A</em></td> <td>SH2 domain containing 1A</td> <td>XLR</td> <td>X-linked lymphoproliferative syndrome 1</td> </tr> <tr class="highlight_lght_gray_text"> <td><em>STAT3</em></td> <td>Signal transducer and activator of transcription 3</td> <td>AD</td> <td>Autoimmune disease, multisystem, infantile onset</td> </tr> <tr> <td><em>STK4</em></td> <td>Serine/threonine kinase 4</td> <td>AR</td> <td>T cell immunodeficiency with recurrent infections, autoimmunity, and cardiac malformations</td> </tr> <tr class="highlight_lght_gray_text"> <td><em>TET2</em></td> <td>Tet methylcytosine dioxygenase 2</td> <td>AR</td> <td>Immunodeficiency 75</td> </tr> <tr> <td><em>TLR8</em></td> <td>Toll-like receptor 8</td> <td>XLR</td> <td>Immunodeficiency 98 with autoinflammation, X linked</td> </tr> <tr class="highlight_lght_gray_text"> <td><em>TNFRSF9</em></td> <td>Tumor necrosis factor receptor superfamily member 9</td> <td>AR</td> <td>4-1BB (CD137) deficiency</td> </tr> <tr> <td><em>XIAP</em></td> <td>X-linked inhibitor of apoptosis</td> <td>XLR</td> <td>X-linked lymphoproliferative syndrome 2</td> </tr> </tbody></table></div><div class="graphic_lgnd">Clinical signs may be present that warrant evaluation for the presence of primary immunodeficiency. Please note that the above table is not comprehensive.</div><div class="graphic_footnotes"><p>AR: autosomal recessive; 
        AD: autosomal dominant; 
        IgE: immunoglobulin E; 
        OMIM: Online Mendelian Inheritance in Man; 
        XLR: X-linked recessive.</p>
    
    * The phenotypic descriptions were derived from OMIM phenotype labels.</div><div id="graphicVersion">Graphic 119237 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
